Astrotech Corporation — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended March 31, 2016 (Astrotech fiscal Q3 2016), with nine-month results through that date. This does not match the request metadata of 2014 Q3.
Business context
Astrotech describes itself as a technology incubator and commercialization company. Its principal activities include 1st Detect chemical analyzers, Astral Images film-restoration and digitization software, and Astrogenetix vaccine and therapeutics research. The former Astrotech Space Operations business was sold in 2014 and is reported as discontinued operations in the prior-year comparison.
Financial performance and liquidity
| Metric | Three months ended March 31, 2016 | Three months ended March 31, 2015 | Nine months ended March 31, 2016 | Nine months ended March 31, 2015 |
|---|---|---|---|---|
| Revenue | $196,000 | $12,000 | $1.123 million | $336,000 |
| Gross profit (loss) | ($158,000) | $12,000 | $137,000 | $55,000 |
| Gross margin | (81%) | 100% | 12% | 16% |
| Operating expenses | $3.778 million | $2.340 million | $10.325 million | $7.988 million |
| Net income (loss) attributable to Astrotech | ($3.742 million) | ($2.100 million) | ($9.632 million) | $18.761 million |
- Quarterly revenue increased by $184,000 year over year, but cost of revenue exceeded revenue, producing a gross loss. Management attributed the quarterly gross loss to the timing of deliverables and said the Battelle project remained gross profitable overall.
- Nine-month revenue rose $787,000. The 2016 period included $881,000 from government-related subcontract agreements and $242,000 from space-grade handrail sales. Nine-month gross margin declined to 12% from 16%.
- Nine-month R&D expense rose to $4.493 million from $2.335 million, primarily due to increased staffing and development at 1st Detect and Astral. SG&A increased to $5.832 million from $5.653 million.
- Nine-month 2015 net income included a $25.630 million gain on the ASO sale; 2016 had no discontinued-operations activity. Continuing-operations losses attributable to Astrotech were $9.632 million for 2016 versus $4.857 million for 2015.
- At March 31, 2016, cash and cash equivalents were $6.073 million, short-term investments $17.658 million, and long-term investments $4.304 million; working capital was approximately $24.2 million. Total cash and investments were approximately $28.0 million, compared with $25.5 million in cash and short-term investments at June 30, 2015.
- Operating cash use for the nine months was $10.954 million, versus $4.844 million from continuing operations in the prior-year period. Investing activities provided $8.698 million from continuing operations, largely reflecting investment sales and maturities. The company had no outstanding debt.
- Current assets were $26.051 million and current liabilities $1.813 million. Total liabilities were $1.926 million; total stockholders’ equity was $31.983 million.
Changes, outlook, and risks
- Astrotech received the $6.1 million ASO-sale indemnity escrow holdback on February 25, 2016; the filing says no further claims may be made against it.
- Management said existing liquidity should be sufficient for operating expenses, capital requirements, and other expected liquidity needs during the next fiscal year. No quantified revenue or earnings guidance is provided.
- Revenue was highly concentrated: three customers accounted for all revenue in fiscal 2016 to date. Smiths Detection represented 89% of quarterly revenue, while Battelle represented 59% of nine-month revenue. The filing identifies reliance on customer contracts, product acceptance, government funding, competition, development milestones, and access to capital as risks.
- The company recorded a full valuation allowance against net deferred tax assets. The nine-month effective tax rate for continuing operations was approximately 0%, compared with 38% in the prior-year period.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. The filing reports no pending or threatened legal proceedings believed likely to have a material adverse effect and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the applicable reporting period: the filing covers fiscal Q3 2016, not 2014 Q3.
- Assess whether the company can convert development and subcontract work into repeatable commercial revenue and improve gross margins.
- Monitor cash burn against management’s liquidity statement, including funding needs for R&D and product development.
- Track customer concentration, contract timing, government-program funding, and progress with Smiths Detection and Battelle.
- Verify reported loss per share: the statements of operations show nine-month 2016 loss per share of $0.47, while a detailed EPS note shows $0.48.